The DOI matches its Crossref record; 60 of the 60 references it cites were found in a registry or an index.
Genome and Transcriptome Sequencing in Prospective Metastatic Triple-Negative Breast Cancer Uncovers Therapeutic Vulnerabilities
Published version of a preprint
Abstract
Triple-negative breast cancer (TNBC) is characterized by the absence of expression of estrogen receptor, progesterone receptor, and HER-2. Thirty percent of patients recur after first-line treatment, and metastatic TNBC (mTNBC) has a poor prognosis with median survival of one year. Here, we present initial analyses of whole genome and transcriptome sequencing data from 14 prospective mTNBC. We have cataloged the collection of somatic genomic alterations in these advanced tumors, particularly those that may inform targeted therapies. Genes mutated in multiple tumors included TP53, LRP1B, HERC1, CDH5, RB1, and NF1. Notable genes involved in focal structural events were CTNNA1, PTEN, FBXW7, BRCA2, WT1, FGFR1, KRAS, HRAS, ARAF, BRAF, and PGCP. Homozygous deletion of CTNNA1 was detected in 2 of 6 African Americans. RNA sequencing revealed consistent overexpression of the FOXM1 gene when tumor gene expression was compared with nonmalignant breast samples. Using an outlier analysis of gene expression comparing one cancer with all the others, we detected expression patterns unique to each patient's tumor. Integrative DNA/RNA analysis provided evidence for deregulation of mutated genes, including the monoallelic expression of TP53 mutations. Finally, molecular alterations in several cancers supported targeted therapeutic intervention on clinical trials with known inhibitors, particularly for alterations in the RAS/RAF/MEK/ERK and PI3K/AKT/mTOR pathways. In conclusion, whole genome and transcriptome profiling of mTNBC have provided insights into somatic events occurring in this difficult to treat cancer. These genomic data have guided patients to investigational treatment trials and provide hypotheses for future trials in this irremediable cancer. Mol Cancer Ther; 12(1); 104–16. ©2012 AACR.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
The Sequence Alignment/Map format and SAMtools
Li, H., Handsaker, B., Wysoker, A., Fennell, T., Ruan, J., Homer, N., Marth, G., Abecasis, G., Durbin, R., & 1000 Genome Project Data Processing Subgroup (2009) · Bioinformatics · doi:10.1093/bioinformatics/btp352 · Cited by 62,041
Robinson, M. D., McCarthy, D. J., & Smyth, G. K. (2010) · Bioinformatics · doi:10.1093/bioinformatics/btp616 · Cited by 41,364
The Genome Analysis Toolkit: A MapReduce framework for analyzing next-generation DNA sequencing data
McKenna, A., Hanna, M., Banks, E., Sivachenko, A., Cibulskis, K., Kernytsky, A., Garimella, K., Altshuler, D., Gabriel, S., Daly, M., et al. (2010) · Genome Research · doi:10.1101/gr.107524.110 · Cited by 27,895
Molecular portraits of human breast tumours
Perou, C. M., Sørlie, T., Eisen, M. B., van de Rijn, M., Jeffrey, S. S., Rees, C. A., Pollack, J. R., Ross, D. T., Johnsen, H., Akslen, L. A., et al. (2000) · Nature · doi:10.1038/35021093 · Cited by 16,261
Comprehensive molecular portraits of human breast tumours
The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11412 · Cited by 12,129
Sørlie, T., Perou, C. M., Tibshirani, R., Aas, T., Geisler, S., Johnsen, H., Hastie, T., Eisen, M. B., van de Rijn, M., Jeffrey, S. S., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.191367098 · Cited by 10,938
Integrated genomic analyses of ovarian carcinoma
Perou, C. M. (2019) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/hvp3-wg08 · Cited by 7,925
A scaling normalization method for differential expression analysis of RNA-seq data
Robinson, M. D., & Oshlack, A. (2010) · Genome Biology · doi:10.1186/gb-2010-11-3-r25 · Cited by 7,876
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
Farmer, H., McCabe, N., Lord, C. J., Tutt, A. N. J., Johnson, D. A., Richardson, T. B., Santarosa, M., Dillon, K. J., Hickson, I., Knights, C., et al. (2005) · Nature · doi:10.1038/nature03445 · Cited by 6,683
Lehmann, B. D., Bauer, J. A., Chen, X., Sanders, M. E., Chakravarthy, A. B., Shyr, Y., & Pietenpol, J. A. (2011) · Journal of Clinical Investigation · doi:10.1172/jci45014 · Cited by 5,592
Cited by
Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease
Bianchini, G., Balko, J. M., Mayer, I. A., Sanders, M. E., & Gianni, L. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.66 · Cited by 3,079
Frampton, G. M., Fichtenholtz, A., Otto, G. A., Wang, K., Downing, S. R., He, J., Schnall-Levin, M., White, J., Sanford, E. M., An, P., et al. (2013) · Nature Biotechnology · doi:10.1038/nbt.2696 · Cited by 2,157
Integrative omics for health and disease
Karczewski, K. J., & Snyder, M. P. (2018) · Nature Reviews Genetics · doi:10.1038/nrg.2018.4 · Cited by 1,158
“In cancer, DNA and RNA sequencing of tumour–normal pairs has identified translocation and gene expression signatures, which has suggested targeted therapies that resulted in disease regression 108,109 .”
BackgroundMetastatic heterogeneity of breast cancer: Molecular mechanism and potential therapeutic targets
Liang, Y., Zhang, H., Song, X., & Yang, Q. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.08.012 · Cited by 992
Translating RNA sequencing into clinical diagnostics: opportunities and challenges
Byron, S. A., Van Keuren-Jensen, K. R., Engelthaler, D. M., Carpten, J. D., & Craig, D. W. (2016) · Nature Reviews Genetics · doi:10.1038/nrg.2016.10 · Cited by 809
Self-citation
Metadata
- Authors
- Craig, D. W., O'Shaughnessy, J. A., Kiefer, J. A., Aldrich, J., Sinari, S., Moses, T. M., Wong, S., Dinh, J., Christoforides, A., Blum, J. L., Aitelli, C. L., Osborne, C. R., Izatt, T., Kurdoglu, A., Baker, A., Koeman, J., Barbacioru, C., Sakarya, O., De La Vega, F. M., Siddiqui, A., Hoang, L., Billings, P. R., Salhia, B., Tolcher, A. W., Trent, J. M., Mousses, S., Von Hoff, D., & Carpten, J. D.
- Affiliations
- Translational Genomics Research Institute (US)
- Authors' Affiliations: 1Translational Genomics Research Institute, Phoenix, Arizona; 2Baylor Sammons Cancer Center, Texas Oncology, US Oncology, Dallas; 3Texas Oncology, US Oncology, Fort Worth; 4South Texas Accelerated Research Therapeutics, START Center for Cancer Care, San Antonio, Texas; 5Van Andel Research Institute, Grand Rapids, Michigan; and 6Life Technologies, Carlsbad, California
- Corresponding author
- Carpten, John D.
- ORCID
- Venue
- Molecular Cancer Therapeutics
- Published
- 2013-01-01
- Volume
- 12
- Issue
- 1
- Pages
- 104-116
- ISSN
- 1535-7163 (ISSN-L)
- 1538-8514
- OpenAlex
- W2134133462
- Cited by
- 220
- References
- 60
- Citations by year
- 2026: 2 · 2025: 8 · 2024: 9 · 2023: 11 · 2022: 11 · 2021: 13 · 2020: 21 · 2019: 12 · 2018: 24 · 2017: 19 · 2016: 26 · 2015: 25 · 2014: 20 · 2013: 19
- FWCI
- 6.77
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Molecular Cancer Therapeutics (publishedVersion)
- PubMed (publishedVersion)
- Funders
- GlaxoSmithKline
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › BRCA gene mutations in cancer
- Keywords
- metastatic triple-negative breast cancer, somatic alterations, TP53 mutation, monoallelic expression, RAS/MAPK pathway, PI3K/AKT/mTOR pathway, targeted therapy, therapeutic vulnerabilities, African American patients, tumor heterogeneity
- MeSH terms
- Forkhead Box Protein M1, Adult, Breast Neoplasms, Chromosomes, Human, Pair 7, DNA Mutational Analysis, Female, Humans, Middle Aged, Neoplasm Metastasis, Prospective Studies, Receptors, Estrogen, Receptors, Progesterone, Signal Transduction, Gene Expression, Genome, Human, Tumor Suppressor Protein p53, Treatment Outcome, Sequence Deletion, Sequence Analysis, RNA, Erb-b2 Receptor Tyrosine Kinases, alpha Catenin, Forkhead Transcription Factors, Genes, Neoplasm, Genome-Wide Association Study, Molecular Targeted Therapy, High-Throughput Nucleotide Sequencing, Transcriptome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Genome and Transcriptome Sequencing in Prospective Metastatic Triple-Negative Breast Cancer Uncovers Therapeutic Vulnerabilities. https://app.cochat.ai/papers/10.1158/1535-7163.mct-12-0781
- The paper
- Craig, D. W., O'Shaughnessy, J. A., Kiefer, J. A., Aldrich, J., Sinari, S., Moses, T. M., Wong, S., Dinh, J., Christoforides, A., Blum, J. L., Aitelli, C. L., Osborne, C. R., Izatt, T., Kurdoglu, A., Baker, A., Koeman, J., Barbacioru, C., Sakarya, O., De La Vega, F. M., . . . Carpten, J. D. (2013). Genome and Transcriptome Sequencing in Prospective Metastatic Triple-Negative Breast Cancer Uncovers Therapeutic Vulnerabilities. Molecular Cancer Therapeutics. https://doi.org/10.1158/1535-7163.mct-12-0781
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.